- Home
- Technology
- Services
- mRNA Display-based Antibody Discovery
- mRNA Display-based Peptide Discovery
- mRNA Display-based Protein Discovery
- Applications
- About
To meet the needs of modern medical diagnosis, innovative methods are needed to effectively detect, monitor and even connect the pathophysiology of patients. With the increasing application of rational and systematic biological design in the development of diagnostics, we are seeing breakthrough methods applied in multiple diagnostic fields to overcome existing challenges and achieve precision medicine. The diagnostic methods based on functional molecules provide real-time, dynamic, sensitive, highly specific and non-invasive methods for detecting and monitoring such as cancer cells, metabolic parameters, infectious sources, therapeutic drugs and toxin exposure. mRNA display technology is being used to produce more functional small molecules using reasonable engineering strategies to develop new biological sensing systems for diagnosis and monitoring in many fields such as medical, agricultural, biological, food and so on.
According to the latest research findings, peptide mimics developed by mRNA display technology have important application value in disease diagnosis and screening, and the most concerned is the application in the detection of COVID-19. In addition, probes, microarrays and chips developed in combination with immunological principles are also widely used in early disease screening tests. CD BioSciences is committed to using this technology to achieve the screening and development of multiple diagnostic tools, promote the development of human diagnostic medicine and promote the early detection of multiple serious diseases.
Most commercial diagnostic tests are based on the detection of proteins associated with specific diseases and depend on the use of antibodies. The antibody discovery platform based on mRNA display technology can develop a variety of antibodies and antibody libraries to meet the needs. Recently, the development of a transverse flow assay based on nanoantibodies (Nbs) for the determination of Trypanosoma Congo infection in plasma was reported. Subsequently, sandwich ELISA was developed and successfully tested in plasma. Finally, a side flow measurement method based on Nbs was developed to measure parasitism, which has good sensitivity and specificity parameters. For the detection of bacteria, some examples of antibody production through active immunization of interested proteins or biomarkers and screening through in vitro display technology can also be found in the literature.
The diagnostic reagents used to detect low-molecular-weight compounds generally produce haptens, which simulate the physical and chemical characteristics of the target analyte, and then prepare and screen the relevant specific binding molecules. The preparation of hapten has been successfully used in many compounds, including targets related to environment, food substrate and biological samples. However, despite achieving excellent analytical characteristics, the use of these binding molecules shows that it is necessary to improve their stability to important internal and external factors, such as temperature or organic solvents. Small molecules developed by mRNA display technology show high tolerance to these factors. The small molecular candidates obtained by in vitro display have small size, are suitable for bioengineering, high solubility and high chemical stability, which enable them to overcome matrix interference and improve the ability of routine diagnosis and analysis.
Today, early diagnosis involves not only in vitro determination of specific biomarkers; There are other very useful applications. These include in vivo diagnostic procedures, such as molecular imaging technology, which is widely used by clinicians to visualize possible disease abnormalities, mainly tumors. In this context, mRNA display technology can be used to design and screen small molecular ligands for targeted delivery and add fluorescent labels. Modification of these small molecules obtained through screening, including fluorophores, enzyme tracers, biotins or different drugs, can be used as good tracers and target tumors or other types of diseases (such as rheumatoid arthritis).
CD BioSciences is committed to discovering small molecular compounds that can be used in various diagnostic forms through mRNA display technology, such as reagent kits, chips, microarrays, etc. Our multiple molecular discovery platforms support customers to search for new potentially effective compounds in antibody, peptide, enzyme, receptor and other aspects to promote early screening of diseases and detection in food, environment, material science and other aspects. If you have any applications or services you want to know, please contact us immediately for the best suggestions and solutions.
